ARROWHEAD PHARMACEUTICALS, INC. Increase Decrease In Operating Lease Liability
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Increase Decrease In Operating Lease Liability of -$3.56 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-04
- ARROWHEAD PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$1.13M.
- ARROWHEAD PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$1.21M.
- ARROWHEAD PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$1.21M.
- ARROWHEAD PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$1.19M.
- ARROWHEAD PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2025 was -$4.61M, a 305.58% decline from fiscal 2024.
- ARROWHEAD PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2024 was $2.24M, a 95.19% decline from fiscal 2023.
- ARROWHEAD PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2023 was $46.59M, a 246.96% increase from fiscal 2022.
- ARROWHEAD PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2022 was $13.43M, a 320.68% increase from fiscal 2021.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 9 month as first filed | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-04 | -$2.35M derived: sum of 2 quarters · filed 2026-08-04 | -$3.56M 10-Q · filed 2026-08-04 | -$4.74M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | -$1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-07 | -$2.42M 10-Q · filed 2026-05-07 | -$3.61M derived: sum of 3 quarters · filed 2026-05-07 | -$4.77M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-12-31 | -$1.21M 10-Q · filed 2026-02-05 | -$2.40M derived: sum of 2 quarters · filed 2026-02-05 | -$3.56M derived: sum of 3 quarters · filed 2026-08-04 | -$4.69M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-09-30 | -$1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | -$2.35M derived: sum of 2 quarters · filed 2026-08-04 | -$3.48M derived: sum of 3 quarters · filed 2026-08-04 | -$4.61M 10-K · filed 2025-11-25 | |
| 2025-06-30 | -$1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-04 | -$2.29M derived: sum of 2 quarters · filed 2026-08-04 | -$3.42M 10-Q · filed 2026-08-04 | -$5.06M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | -$1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-07 | -$2.25M 10-Q · filed 2026-05-07 | -$3.90M derived: sum of 3 quarters · filed 2026-05-07 | -$4.43M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$1.13M 10-Q · filed 2026-02-05 | -$2.77M derived: sum of 2 quarters · filed 2026-02-05 | -$3.31M derived: sum of 3 quarters · filed 2026-02-05 | -$2.68M derived: sum of 4 quarters · filed 2026-02-05 | |
| 2024-09-30 | -$1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | -$2.18M derived: sum of 2 quarters · filed 2025-11-25 | -$1.56M derived: sum of 3 quarters · filed 2025-11-25 | $2.24M 10-K · filed 2025-11-25 | |
| 2024-06-30 | -$537.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-07 | $84.00K derived: sum of 2 quarters · filed 2025-08-07 | $3.88M 10-Q · filed 2025-08-07 | $48.64M derived: sum of 4 quarters · filed 2025-11-25 | |
| 2024-03-31 | $621.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-12 | $4.42M 10-Q · filed 2025-05-12 | $49.18M derived: sum of 3 quarters · filed 2025-11-25 | $49.80M derived: sum of 4 quarters · filed 2025-11-25 | |
| 2023-12-31 | $3.80M 10-Q · filed 2025-02-10 | $48.56M derived: sum of 2 quarters · filed 2025-11-25 | $49.18M derived: sum of 3 quarters · filed 2025-11-25 | $49.83M derived: sum of 4 quarters · filed 2025-11-25 | |
| 2023-09-30 | $44.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $45.38M derived: sum of 2 quarters · filed 2025-11-25 | $46.03M derived: sum of 3 quarters · filed 2025-11-25 | $46.59M 10-K · filed 2025-11-25 | |
| 2023-06-30 | $622.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-08 | $1.27M derived: sum of 2 quarters · filed 2024-08-08 | $1.83M 10-Q · filed 2024-08-08 | $1.16M 10-Q · filed 2023-08-07 | $11.52M derived: sum of 4 quarters · filed 2024-11-26 |
| 2023-03-31 | $646.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-09 | $1.21M 10-Q · filed 2024-05-09 | $10.90M derived: sum of 3 quarters · filed 2024-11-26 | $14.05M derived: sum of 4 quarters · filed 2024-11-26 | |
| 2022-12-31 | $559.00K 10-Q · filed 2024-02-06 | $10.25M derived: sum of 2 quarters · filed 2024-11-26 | $13.41M derived: sum of 3 quarters · filed 2024-11-26 | $13.76M derived: sum of 4 quarters · filed 2024-11-26 | |
| 2022-09-30 | $9.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | $12.85M derived: sum of 2 quarters · filed 2024-11-26 | $13.20M derived: sum of 3 quarters · filed 2024-11-26 | $13.43M 10-K · filed 2024-11-26 | |
| 2022-06-30 | $3.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | $3.50M derived: sum of 2 quarters · filed 2023-08-07 | $3.73M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $350.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-02 | $580.00K 10-Q · filed 2023-05-02 | |||
| 2021-12-31 | $230.00K 10-Q · filed 2023-02-06 | ||||
| 2021-09-30 | $3.19M 10-K · filed 2023-11-29 | ||||
| 2020-09-30 | $1.12M 10-K · filed 2022-11-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |